Drug Type Small molecule drug |
Synonyms CX 1026, CX1026 |
Target |
Action inhibitors, antagonists |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), HDAC6 inhibitors(Histone deacetylase 6 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colonic Cancer | Preclinical | China | 29 May 2024 | |
| Cutaneous T-Cell Lymphoma | Preclinical | China | 29 May 2024 | |
| Kidney Neoplasms | Preclinical | China | 29 May 2024 | |
| Liver Cancer | Preclinical | China | 29 May 2024 | |
| Lung Cancer | Preclinical | China | 29 May 2024 | |
| Acute Myeloid Leukemia | Preclinical | China | 30 Jan 2022 | |
| Non-Small Cell Lung Cancer | Preclinical | China | 30 Jan 2022 | |
| Stomach Cancer | Preclinical | China | 30 Jan 2022 |





